HomepageATYR • NASDAQ
add
aTyr Pharma Inc
$ 0,89
Na sluitingstijd:(0,60%)+0,0054
$ 0,90
Gesloten: 16 mrt, 19:32:47 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 0,85
Dag-range
$ 0,84 - $ 0,90
Jaar-range
$ 0,64 - $ 7,29
Beurswaarde
87,71 mln. USD
Gem. volume
1,83 mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 3,90 mln. | 8,71% |
Netto inkomsten | -13,96 mln. | 6,71% |
Netto winstmarge | — | — |
Winst per aandeel | -0,14 | 22,22% |
EBITDA | -14,63 mln. | 6,49% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 78,69 mln. | 9,10% |
Totale activa | 93,00 mln. | -3,95% |
Totale passiva | 25,72 mln. | -4,75% |
Totaal aandelenvermogen | 67,29 mln. | — |
Uitstaande aandelen | 98,05 mln. | — |
Koers-boekwaardeverhouding | 1,23 | — |
Rendement op activa | -37,05% | — |
Rendement op kapitaal | -43,08% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -13,96 mln. | 6,71% |
Operationele kasstroom | -12,20 mln. | 7,13% |
Kasstroom uit beleggingen | 16,44 mln. | 370,22% |
Kasstroom uit financiering | -131,00K | -100,70% |
Nettomutatie in liquide middelen | 4,12 mln. | 1.188,89% |
Vrije kasstroom | -6,98 mln. | 10,87% |
Over
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Opgericht
1 jan 2005
Website
Werknemers
59
